ClinicalTrials.gg
CompletedNCT01736254Updated Oct 3, 2018Results posted

A Study of Evacetrapib in Healthy Participants

A Phase 1 interventional study of Evacetrapib and Gemfibrozil in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-03.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine whether concentrations of the study drug (evacetrapib) in the blood stream is the same or is different when the person is also taking gemfibrozil (a drug used to lower lipid levels). Each participant will receive gemfibrozil alone, evacetrapib alone, and both drugs in combination. There is no washout period between doses. The safety of both of the study drugs given together will be evaluated. Information about any side effects that may have occurred will also be collected. This study will last approximately 36 days.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy participants as determined by medical history and physical examination
  • Have a of 18 to 32 kilograms per square meter (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • Have known allergies to evacetrapib and gemfibrozil, related compounds or any components of the formulation
  • Have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Currently smoke cigarettes or use tobacco or nicotine substitutes
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Gemfibrozil

    Single oral dose of 600 milligrams (mg) gemfibrozil on Day 1

    Drug: Gemfibrozil

  • Experimental
    Evacetrapib

    Oral doses of 130 mg evacetrapib once a day (QD) for 10 days (Day 2 through Day 12)

    Drug: Evacetrapib

  • Experimental
    Evacetrapib + Gemfibrozil

    Oral doses of 600 mg gemfibrozil twice a day (BID) and 130 mg evacetrapib QD for 10 days (Day 13 through Day 22). Single oral dose of 600 mg gemfibrozil on Day 23.

    Drug: Evacetrapib · Drug: Gemfibrozil

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib

    Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Day 11 and Day 22

  2. Pharmacokinetics (PK): Area Under the Concentration Curve Over a 24 Hour Dosing Interval (AUCτ) of Evacetrapib

    Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Day 11 and Day 22

  3. Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Evacetrapib

    Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Day 11 and Day 22

Secondary outcomes

  1. Pharmacokinetics (PK): Area Under the Concentration Curve Over a 12 Hour Dosing Interval (AUCτ) of Gemfibrozil

    Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Day 1 and Day 13

  2. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Gemfibrozil

    Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Day 1 and Day 13

  3. Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Gemfibrozil

    Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib.

    Time frame: Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Day 1 and Day 13

07

Results

Posted Oct 3, 2018

Participant flow

Period 1 (Day 1)
Participant flow — Period 1 (Day 1)
MilestoneAll Participants
Started24
Received at least one dose of study drug24
Completed24
Not completed0
Period 2 (Days 2 to 12)
Participant flow — Period 2 (Days 2 to 12)
MilestoneAll Participants
Started24
Completed21
Not completed3
Withdrew: Adverse event3
Period 3 (Days 13 to 23)
Participant flow — Period 3 (Days 13 to 23)
MilestoneAll Participants
Started21
Completed20
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib

Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Day 11 and Day 22
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib
nanograms/milliliter (ng/mL)EvacetrapibEvacetrapib + Gemfibrozil
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Evacetrapib1270 ± 261290 ± 26
PrimaryPharmacokinetics (PK): Area Under the Concentration Curve Over a 24 Hour Dosing Interval (AUCτ) of Evacetrapib

Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Day 11 and Day 22
Reported as:
Geometric mean · nanograms*hours/milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Curve Over a 24 Hour Dosing Interval (AUCτ) of Evacetrapib
nanograms*hours/milliliter (ng*h/mL)EvacetrapibEvacetrapib + Gemfibrozil
Pharmacokinetics (PK): Area Under the Concentration Curve Over a 24 Hour Dosing Interval (AUCτ) of Evacetrapib11300 ± 2011400 ± 21
PrimaryPharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Evacetrapib

Venous blood samples were taken on Day 11 for PK parameter estimates of evacetrapib alone and on Day 22 for PK parameter estimates of evacetrapib when coadministered with gemfibrozil.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours postdose on Day 11 and Day 22
Reported as:
Median · hours
Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Evacetrapib
hoursEvacetrapibEvacetrapib + Gemfibrozil
Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Evacetrapib4.00 (2.02 to 6.00)3.00 (2.00 to 4.00)
SecondaryPharmacokinetics (PK): Area Under the Concentration Curve Over a 12 Hour Dosing Interval (AUCτ) of Gemfibrozil

Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Day 1 and Day 13
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics (PK): Area Under the Concentration Curve Over a 12 Hour Dosing Interval (AUCτ) of Gemfibrozil
ng*h/mLGemfibrozilEvacetrapib + Gemfibrozil
Pharmacokinetics (PK): Area Under the Concentration Curve Over a 12 Hour Dosing Interval (AUCτ) of Gemfibrozil55700 ± 2353800 ± 22
SecondaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Gemfibrozil

Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Day 1 and Day 13
Reported as:
Geometric mean · ng/mL
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Gemfibrozil
ng/mLGemfibrozilEvacetrapib + Gemfibrozil
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Gemfibrozil17400 ± 3216800 ± 34
SecondaryPharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Gemfibrozil

Venous blood samples were taken on Day 1 for PK parameter estimates of gemfibrozil alone and on Day 13 for PK parameter estimates of gemfibrozil when coadministered with evacetrapib.

Time frame:
Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours postdose on Day 1 and Day 13
Reported as:
Median · hours
Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Gemfibrozil
hoursGemfibrozilEvacetrapib + Gemfibrozil
Pharmacokinetics (PK): Time of Maximum Observed Drug Concentration (Tmax) of Gemfibrozil1.00 (1.00 to 4.00)1.08 (1.08 to 4.00)

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gemfibrozil—0/24 (0%)1/24 (4.2%)
Evacetrapib—0/24 (0%)8/24 (33.3%)
Evacetrapib + Gemfibrozil—0/21 (0%)7/21 (33.3%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventGemfibrozilEvacetrapibEvacetrapib + Gemfibrozil
Pain in extremityMusculoskeletal and connective tissue disorders0/240/242/21
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/242/240/21
Ocular hyperaemiaEye disorders0/240/241/21
DiarrhoeaGastrointestinal disorders0/240/241/21
Decreased appetiteMetabolism and nutrition disorders0/240/241/21
HeadacheNervous system disorders0/240/241/21
Dry throatRespiratory, thoracic and mediastinal disorders0/240/241/21
AcneSkin and subcutaneous tissue disorders0/240/241/21
PruritusSkin and subcutaneous tissue disorders0/241/241/21
RashSkin and subcutaneous tissue disorders0/240/241/21

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)All Participants
Mean41.8 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female2
Male22
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
White14
Black7
Multiple3
Region of Enrollment
Region of Enrollment(Participants)All Participants
United States24
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Daytona Beach, Florida 32117, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2012, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2018, 5 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2012
First posted
Nov 29, 2012
Start
Dec 2012
Primary completionActual
Feb 2013
CompletionActual
Feb 2013
Results first posted
Oct 3, 2018
Last update
Oct 3, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01736254
Responsible party
Sponsor
First posted
Nov 29, 2012
Start date
Dec 2012
Primary completion
Feb 2013
Completion
Feb 2013
Results posted
Oct 3, 2018
Last update
Oct 3, 2018

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Evacetrapib · Gemfibrozil

Start the discussion